SCHEMBL24185232

SCHEMBL24185232

CC(C)(C)OC(=O)N[C@H]1CCN(C(=O)c2ccc(Br)cc2)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.56
KMT2A Q03164 2/20 0.52
POLB P06746 1/20 0.52
PARP1 P09874 1/20 0.51
HSD11B1 P28845 3/20 0.50
CYP2C9 P11712 1/20 0.50
USP30 Q70CQ3 1/20 0.49
CTSK P43235 2/20 0.49
FPR3 P25089 1/20 0.48
FPR2 P25090 1/20 0.48
EPHX2 P34913 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CFTR P13569 1/20 0.47
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
NPC1L1 Q9UHC9 1/20 0.45
L3MBTL3 Q96JM7 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24185215 1.00 NAMPT (0.56) NAMPTKMT2APOLBPARP1HSD11B1
SCHEMBL24185784 1.00 NAMPT (0.56) NAMPTKMT2APOLBPARP1HSD11B1
SCHEMBL2610296 0.90 NAMPT (0.49) NAMPTKMT2APOLBCTSKFPR3
SCHEMBL31267054 0.89 NAMPT (0.57) NAMPTKMT2APARP1HSD11B1CYP2C9
SCHEMBL31267093 0.89 NAMPT (0.57) NAMPTKMT2APARP1HSD11B1CYP2C9
SCHEMBL4618429 0.88 MEN1 (0.59) NAMPTKMT2APARP1HSD11B1CYP2C9
SCHEMBL7939466 0.88 NAMPT (0.61) NAMPTKMT2APARP1HSD11B1CYP2C9
SCHEMBL2610266 0.88 NAMPT (0.61) NAMPTKMT2APARP1HSD11B1CYP2C9
SCHEMBL12644375 0.86 NAMPT (0.70) NAMPTKMT2APARP1HSD11B1CYP2C9
SCHEMBL16771644 0.85 NAMPT (0.53) NAMPTPARP1HSD11B1CYP2C9USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2023-11-23 US disclosed
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2023-11-23 US disclosed
WO-2022011337-A1 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2022-01-13 WO disclosed
WO-2022011338-A2 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2022-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF TYK2, MAPKAPK2, MAP3K20 NAMPT 1179/4885KMT2A 630/4885POLB 1388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.